BIO-key International, Inc. Reports Strong Q1 2026 Results: Revenue Growth and Path to Profitability
Key Financial Highlights and Strategic Outlook for Investors
BIO-key International, Inc. (NASDAQ: BKYI), a leading provider of identity and access management (IAM) solutions, has released its financial results for the first quarter of 2026, demonstrating a significant improvement in both top-line and bottom-line performance. The company also provided a bullish outlook for the upcoming quarters, signaling potential positive momentum for its share price.
Key Highlights from Q1 2026 Report
- Q1 2026 revenues rose 34% year-over-year to \$2.15 million, and were up 74% sequentially from Q4 2025. This strong revenue growth outpaced expectations and marked a robust start to the year.
- Net loss narrowed to \$(165,000) in Q1 2026, a substantial improvement compared to a net loss of \$(737,000) in Q1 2025 and \$(1.722 million) in Q4 2025. The company is clearly moving closer to profitability.
- Cash and cash equivalents stood at \$2.24 million at the end of Q1 2026, showing a stable liquidity position.
- Shares outstanding at quarter-end were 1.08 million.
Outlook and Guidance: Bullish Signals for Investors
- Q2 2026 revenues are expected to rise 65% year-over-year to approximately \$2.8 million (compared to \$1.7 million in Q2 2025).
- First half (H1) 2026 revenues are projected to increase 50% to around \$5 million (versus \$3.3 million in H1 2025).
- Profitability is expected in H1 2026, in contrast to a net loss of \$(1.9 million) in H1 2025.
- The company expects its cash position at the end of H1 2026 to be in line with the current level, which indicates prudent cash management.
Management Commentary and Strategic Updates
According to management, BIO-key’s business is off to a “strong start” in 2026, with a positive outlook for Q2 and the remainder of the year. The company believes it is “better positioned than ever for growth and improved financial performance.” This upbeat commentary, combined with the return to profitability guidance, could be a significant catalyst for the stock price.
The company also noted that, while it is actively working to return its shares to the Nasdaq Capital Market, its common stock continues to trade on the OTC Markets under the symbol BKYI. The timing and success of the relisting effort remain uncertain, but this is an important factor for investors to monitor as it could impact liquidity and valuation.
Financial Statement Review
- Balance Sheet: At March 31, 2026, the company reported total assets of \$7.43 million, including \$2.24 million in cash and cash equivalents, and \$5 million in investments. Stockholders’ equity stood at \$7.43 million, with 10,852,118 shares issued and outstanding.
- Income Statement: For Q1 2026, revenue was \$2.15 million. Operating expenses, mainly in selling, general, and administrative costs, totaled \$1.27 million. Total operating expenses were \$1.87 million, resulting in a net loss of \$(165,036), a marked improvement from previous periods. Basic and diluted loss per share was \$(0.15), compared to \$(1.57) in Q1 2025.
Note: The Q1 2026 financial statements have not yet been reviewed by the company’s independent registered public accounting firm and may be subject to change.
Potential Share Price Catalysts
- Return to Profitability: The expectation of profitability in H1 2026 is a major milestone and could be a significant driver for share price appreciation.
- Accelerated Revenue Growth: The company projects continued strong revenue growth in Q2 and beyond, with guidance implying continued operational momentum.
- Cash Position Stability: Maintaining a stable cash position despite growth investments should reassure investors regarding liquidity and going-concern risks.
- Nasdaq Relisting Efforts: Progress on regaining a Nasdaq listing could improve the stock’s visibility and liquidity, potentially supporting valuation upside.
Risks and Considerations
- History of losses, though improving.
- Ongoing uncertainty around relisting on Nasdaq, which could impact trading volume and investor interest.
- Financial statements for Q1 2026 are preliminary and subject to revision.
- General risks associated with raising additional capital if needed, competitive pressures, and execution on growth plans.
Engage with BIO-key
For more information, investors can follow BIO-key on their corporate social media channels:
- Facebook: BIO-key International
- LinkedIn: BIO-key International
- X (Twitter) Corporate: @BIOkeyIntl
- X (Twitter) Investors: @BIO_keyIR
- StockTwits: BIO_keyIR
Investor Contact: William Jones, David Collins at Catalyst IR ([email protected], 212-924-9800)
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All statements contained herein, other than statements of historical fact, are forward-looking statements and are subject to risks and uncertainties. Please refer to the company’s SEC filings for more detailed risk factors. The financial statements referenced are preliminary and unaudited and may be subject to change.
